<DOC>
	<DOCNO>NCT00771498</DOCNO>
	<brief_summary>This pharmacokinetic , descriptive , open-label , prospective , multicentric , national study Aids tuberculosis co-infected patient , laboratory clinically monitor treatment lopinavir-ritonavir rifampin medication . Study population : Thirty patient older 18 year , male female , present active tuberculosis failure contraindication motive efavirenz select participate study . Objectives : - Evaluate pharmacokinetics lopinavir-800mg / ritonavir-200mg combination ( every 12 h ) association rifampin-containing anti-tuberculosis regimen , patient present tuberculosis HIV-infected indication antiretroviral treatment accord Brazilian Ministry Health 's guideline , contraindication use NNTRI . - Describe adverse event observe tuberculosis treatment period rifampin associate antiretroviral therapy consist lopinavir-800mg / ritonavir-200mg every 12 hour . - Describe clinical , immunological virological endpoint throughout study drug .</brief_summary>
	<brief_title>An Evaluation Pharmacological Interaction Lopinavir/r Rifampin</brief_title>
	<detailed_description>Some attempt make evaluate pharmacokinetics lopinavir use ritonavir booster researcher dosages 400/100 533/133 mg ( last dosage would achieve additional capsule lopinavir/ritonavir ) result disappoint AUC importantly decrease introduction rifampin situation ( BERTZ et al , 2000 ) . La Porte et al ( 2004 ) present result pharmacokinetic study use two dosage regimen , lopinavir-400mg/ritonavir-400mg lopinavir-800mg/ritonavir-200mg co-administered rifampin healthy volunteer . With dos , AUCs reestablish , use increase dose ritonavir , double dose lopinavir/ritonavir . However , minimum plasma concentration combination lopinavir 800mg-ritonavir 200mg low timepoints recommend achieve good virologic effect . The reported adverse event , headache , nausea , diarrhea , fatigue abdominal pain/cramps , similar arm . However , high rate liver toxicity lopinavir-400mg/ritonavir-400mg dose arm , grade 2/3 ALT/SGTP elevation occur 5 subject compare 2 subject lopinavir-800mg/ritonavir-200mg dose arm . Virological suppression evaluate pharmacokinetic study healthy volunteer . In case , liver toxicity might explain high ritonavir dos , strategy reduce ritonavir dosage permit low incidence liver toxicity gastrointestinal event would extreme practical utility . Recently , WHO ( WHO , 2003 ) CDC ( MMWR , 2004 ) recommend lopinavir 400mg-ritonavir 400mg every 12 hour combination rifampin country limit resource , base solely study healthy volunteer ( La PORTE , 2004 ) . In spite significant contribution knowledge interaction among drug , study reproduce reality clinical practice , volunteer healthy , antiretroviral anti-tuberculosis regimen give full dos lopinavir-ritonavir introduce first rifampin add 14 day . In clinical practice , tuberculosis treatment priority ( BRASIL , Ministério da Saúde , 2006 ) , antiretroviral regimen start later , period least 30 day , order observe tolerability adverse event usually occur within first month tuberculosis treatment ( PEDRAL-SAMPAIO 1997 ) . The scientific community react surprise recommendation evidence HIV-infected patient , antiretroviral drug rifampin combination safe describe healthy volunteer , well concern frequency adverse event may occur combination . Furthermore , effort make establish evidence support use potent antiretroviral agent within context rescue regimen , among HAART-experienced patient . The perspective another therapeutic possibility may use concomitantly rifampin rescue medication HIV-infected patient present tuberculosis fail antiretroviral regimen may represent option . Therapeutic regimen tuberculosis without rifampin less efficient , extend negative baciloscopy , associate big mortality besides long ( 1 year ) use injectable drug first 3 month ( streptomycin ) . Because lopinavir drug increase genetic barrier resistance ( MENDOZA &amp; SORIANO , 2004 ) may represent excellent therapeutic option patient antiretroviral alternative . In Brazil , current market soft gel capsule formulation Kaletra ( lopinavir/ritonavir ) present limitation need refrigeration moderately elevate incidence rate diarrhea adverse event , 25 28 % , among antiretroviral naïve experience patient ( MURPHY et al , 2005 ; FEINBERG et al , 2000 ) . Recently , FDA ( Food Drug Administration , EUA ) approve new Kaletra ( lopinavir/ritonavir ) tablet formulation . The new formulation base Meltrex™ ( melt extrusion ) technology , require refrigeration ( AWNI et al , 2005 ) . Kaletra ( lopinavir/ritonavir ) tablet show low incidence diarrhea , pharmacokinetic study healthy volunteer , compare result find study use soft gel capsule ( 17.4 % ) ( KLEIN et al , 2005 ) . This scenario seem favourable country like Africa , refrigerator limitant condition patient treatment site . A strategy use tablet , without additional ritonavir seem promise . Taking account : ( 1 ) complexity coinfection tuberculosis-HIV limited treatment option infection , well urgent need evaluate new option antiretroviral regimen ; ( 2 ) The result La Porte et al ( 2004 ) , develop pharmacokinetic study pharmacokinetic drug interaction two different dos lopinavir/ritonavir co-administered rifampin ( 600 mg/day ) evaluate ; ( 3 ) pharmacokinetic study present Awni et al ( 2005 ) , show pharmaceutic equivalence Kaletra ( lopinavir/ritonavir ) soft gel capsule tablet ; propose clinical study TB-HIV coinfected subject use association lopinavir-ritonavir tablet rifampin evaluate pharmacokinetics safety . This study may benefit patient co-infected TB/HIV , particularly advanced immunodeficiency show failure antiretroviral regimen include efavirenz may contraindication use ( hypersensitivity intolerance ) . Thirty patient older 18 year , male female , present active tuberculosis failure contraindication motive efavirenz select participate study . Antiretroviral treatment consist two NRTIs combination associate nucleotide analogue ( tenofovir ) combination lopinavir-800 mg ritonavir-200 mg ( 4 tablet Kaletra ) every 12 hour , daily orally . A genotyping screening conduct order optimize combination therapy . Antituberculosis treatment consist rifampin ( 600 mg/daily ) isoniazide ( 400 mg/daily ) , fast condition 6 month ; pirazinamide ( 2.000 mg ) first two month , accord Ministry Health recommendation . Doses adjusted subject weight less 45 kg . For patient re-treated tuberculosis , etambutol add dose 1.200 mg/daily 6-month treatment . Those patient need use alternative regimen ( without rifampin ) exclude study . In case occurrence gastrointestinal intolerance rifampin , one may use breakfast , data record patient chart order correlate pharmacokinetics data . Lopinavir-Ritonavir start 1 month begin antituberculosis treatment , visit 30 day . The Lopinavir-Ritonavir dosage titrate first week treatment , follow : 1. Days 30 , 31 32 : patient receive lopinavir-ritonavir 400/100 mg ( 2 tablet ) every 12 hour . 2 . On Days 33 , 34 35 : patient receive lopinavir-ritonavir 600/150 mg ( 3 tablet ) every 12 hour . 3 . From Day 36 day 180 : patient receive lopinavir-ritonavir 800/200mg ( 4 tablet ) every 12 hour , unless reduce day 60 ( refer section 14.6 ) . After 6 month tuberculosis treatment , patient fulfills clinical bacteriological criterion cure , antituberculosis drug withdraw lopinavir-ritonavir ( Kaletra® ) maintain . However , dose Kaletra® ( lopinavir/ritonavir ) reduce lopinavir 400mg / ritonavir 100mg ( 2 tablet ) every 12 hour . BERTZ A ; HSU W ; LAM L ; ET AL . Pharmacokinetics interaction Kaletra non HIV drug . 5th International Congress drug therapy HIV infection . Glasgow UK October 22-26 2000 . Poster 438 . BRASIL , MINISTÉRIO DA SAÚDE , 2006 . Recomendações para tratamento de adultos e adolescentes infectados pelo virus HIV . EINBERG J , BRUN S , MARSS T , KING M , BENSON C , DEEKS S , KESSLER H , MURPHY R , GULICK R , WHEELER D , HICKS C , ERON J , SAX P , STRYKER R , RIDDLER S , THOMPSON M , REAL K , HSU A , BERTZ R , KEMPF D , JAPOUR A , SUN E. Durable Suppression HIV+ RNA After Two Years Kaletra ( ABT-378/ritonavir ) Therapy Single Protease Inhibitor Experienced Patients . 5th International Congress Drug Therapy HIV Infection , Glasgow , UK ( October 22-26 , 2000 ) LA PORTE CJL ; COLBERS EPH ; BERTS ET AL . Pharmacokinetics adjusted-dose lopinavir-ritonavir combine rifampin healthy volunteer . Antimicrob . Agents Chemother 48:1553-1560 2004 MMWR Updated guideline use rifamycins treatment tuberculosis among HIV-infected patient take protease inhibitor Nonnucleoside reverse transcriptase inhibitor , version 1.20.2004 MENDOZA , C. &amp; SORIANO , V. Resistance HIV protease inhibitor : mechanisms clinical consequence . Curr . Drug Metab. , 5 ( 4 ) :321-8 , 2004 . MURPHY R , DA SILVA B , McMILLAN F , HICKS C , ERON J , WOLFE P , GULICK R , GLESBY M , THOMPSON M , BENSON C , WHITE AC , ALBRETCH M , KESSLER H , NIEMI K , KING K , CALHOUN D , KING M , HANNA G , BRUN S. Seven Year Follow-up Lopinavir/ritonavir ( LPV/r ) -Based Regimen Antiretroviral ( ARV ) -Naïve Subjects . 10th EACS , Dublin 2005 . Poster PE7.9/3 . PEDRAL-SAMPAIO DB , NETTO EM , ALCÂNTARA AP , SOUZA J , MOURA L , BRITES C ET AL . Use Standard Therapy Tuberculosis Associated Increased Adverse Reactions Patients HIV . BJID , 1 ( 3 ) : 123-130 , 1997 ; WHO ( WORLD HEALTH ORGANIZATION ) . Scaling antiretroviral therapy resource-limited setting . Guidelines public health approach , 2003 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Male female subject , HIV infection active tuberculosis diagnosis . Women must negative pregnancy test use birth control method ( barrier DepoProvera contraceptive ) throughout study investigator 's discretion consider reliable . To guarantee security volunteer pregnancy test urine repeat visit . Patients present contraindication NNRTI use . Contraindication may obtain history virologic resistance ( prior use efavirenz comproved virologic failure subject good adherence ) , genotyping test indicative mutation provide resistance drug , intolerance , hypersensitivity . Patients must older 18 year . HIV infection document two positive ELISA test HIV one confirmatory test ( immunoblot immunofluorescence ) , may replace plasma VL use RochePCR test , Chiron Branched DNA NASBA ( BioMerrieux ) . The tuberculosis diagnostic prove one positive culture identification M. tuberculosis . Besides , patient eligible he/she present clinical sign symptom suggestive tuberculosis , radiological aspect compatible , oportunistic deseases exclude , even specimen baciloscopy negative , accord Brazilian Guidelines ( BRASIL , Ministério da Saúde , 2004 ) ; Patients require use medication establish contraindication concomitant use lopinavirritonavir , : amiodarone , astemizole , bepridil , bupropione , cisapride , clorazepate , clozapim , diazepam , encainide , flecainide , flurazepam , meperidine , midazolam , primozide , piroxicam , propafenone , propoxifeno , quinidine , rifabutin , terfenadine , triazolam , zolpidem , dihydroergotamine ergotamine . Patient agree use medication ( even herbal medication natural product ) without previous knowledgement consent investigator throughout study . Patient also agree notify investigator medication change ( start replace ) study . Patients date sign volunteer inform consent enter study full explanation study nature . If patient unable , his/her legally authorize representative sign his/her behalf . Patient previous history hypersensitivity know resistance acquire rifampin lopinavirritonavir . 2 . Evidence toxic substance abuse , alcohol and/or illicit drug ( Attachment B ) . Viral B and/or C hepatitis coinfection . Patient present one abnormality follow blood laboratory test : STGO and/or STGP and/or alkaline phosphatase &gt; 5,1 fold upper normal limit , bilirrubin &gt; 1.5 mg/dl . If patient eligible moment due risk hepatotoxicity , alternative treatment tuberculosis offer ( accord recommendation Ministry Health ) order reduce risk serious hepatopaty allow use concomitant antiretroviral scheme . This patient exclude study , able treat accompanied responsible site study end tuberculosis treatment wish patient . Documented genotypic resistance lopinavir/ritonavir screen sample . In investigator 's opinion , patient predicts low compliance propose study accord clinical history give subject . Patient history prior use Kaletra® ( lopinavir , ritonavir ) comproved virologic genotypic failure serious intolerance need change antiretroviral treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>rifampin</keyword>
	<keyword>lopinavir</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>